{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T04:46:30Z","timestamp":1795063590334,"version":"4.10.2"},"reference-count":176,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Herlev and Gentofte Hospital","id":[{"id":"https:\/\/ror.org\/051dzw862","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002918","name":"Copenhagen University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002918","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Previous interest in high-density lipoproteins (HDLs) focused on their possible protective role in atherosclerotic cardiovascular disease (ASCVD). Evidence from genetic studies and randomized trials, however, questioned that the inverse association of HDL-cholesterol (HDL-C) is causal. This review aims to provide an update on the role of HDL in health and disease, also beyond ASCVD. Through evolution from invertebrates, HDLs are the principal lipoproteins, while apolipoprotein B-containing lipoproteins first developed in vertebrates. HDLs transport cholesterol and other lipids between different cells like a reusable ferry, but serve many other functions including communication with cells and the inactivation of biohazards like bacterial lipopolysaccharides. These functions are exerted by entire HDL particles or distinct proteins or lipids carried by HDL rather than by its cholesterol cargo measured as HDL-C. Neither does HDL-C measurement reflect the efficiency of reverse cholesterol transport. Recent studies indicate that functional measures of HDL, notably cholesterol efflux capacity, numbers of HDL particles, or distinct HDL proteins are better predictors of ASCVD events than HDL-C. Low HDL-C levels are related observationally, but also genetically, to increased risks of infectious diseases, death during sepsis, diabetes mellitus, and chronic kidney disease. Additional, but only observational, data indicate associations of low HDL-C with various autoimmune diseases, and cancers, as well as all-cause mortality. Conversely, extremely high HDL-C levels are associated with an increased risk of age-related macular degeneration (also genetically), infectious disease, and all-cause mortality. HDL encompasses dynamic multimolecular and multifunctional lipoproteins that likely emerged during evolution to serve several physiological roles and prevent or heal pathologies beyond ASCVD. For any clinical exploitation of HDL, the indirect marker HDL-C must be replaced by direct biomarkers reflecting the causal role of HDL in the respective disease.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehac605","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T09:14:45Z","timestamp":1665479685000},"page":"1394-1407","source":"Crossref","is-referenced-by-count":390,"title":["High-density lipoprotein revisited: biological functions and clinical relevance"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1666-2266","authenticated-orcid":false,"given":"Arnold","family":"von Eckardstein","sequence":"first","affiliation":[{"name":"Institute of Clinical Chemistry, University Hospital Zurich and University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-7220","authenticated-orcid":false,"given":"B\u00f8rge G","family":"Nordestgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital, Herlev and Gentofte Hospital , Herlev , Denmark"},{"name":"The Copenhagen General Population Study, Copenhagen University Hospital, Herlev and Gentofte Hospital , Herlev , Denmark"},{"name":"Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5839-7280","authenticated-orcid":false,"given":"Alan T","family":"Remaley","sequence":"additional","affiliation":[{"name":"Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health , Bethesda, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L","family":"Catapano","sequence":"additional","affiliation":[{"name":"Department of Pharmacological and Biomolecular Sciences, University of Milan , Milan , Italy"},{"name":"IRCCS MultiMedica, Sesto S. Giovanni , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"2023042102571721900_ehac605-B1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1152\/physrev.1954.34.3.589","article-title":"Lipoproteins, coronary heart disease, and atherosclerosis","volume":"34","author":"Gofman","year":"1954","journal-title":"Physiol Rev"},{"key":"2023042102571721900_ehac605-B2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/bmj.2.6134.388","article-title":"Severity of coronary atherosclerosis related to lipoprotein concentration","volume":"2","author":"Jenkins","year":"1978","journal-title":"Br Med J"},{"key":"2023042102571721900_ehac605-B3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0140-6736(75)92376-4","article-title":"Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease","volume":"305","author":"Miller","year":"1975","journal-title":"Lancet"},{"key":"2023042102571721900_ehac605-B4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.ATV.8.6.737","article-title":"High density lipoprotein cholesterol and mortality. The framingham heart study","volume":"8","author":"Wilson","year":"1988","journal-title":"Arteriosclerosis"},{"key":"2023042102571721900_ehac605-B5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The framingham study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"key":"2023042102571721900_ehac605-B6","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels. The framingham study","volume":"256","author":"Castelli","year":"1986","journal-title":"Jama"},{"key":"2023042102571721900_ehac605-B7","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the atherosclerosis risk in communities (ARIC) study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"key":"2023042102571721900_ehac605-B8","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Emerging Risk Factors Collaboration","year":"2009","journal-title":"JAMA"},{"key":"2023042102571721900_ehac605-B9","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"HPS3\/TIMI55\u2013REVEAL Collaborative Group","year":"2017","journal-title":"N Engl J Med"},{"key":"2023042102571721900_ehac605-B10","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"2023042102571721900_ehac605-B11","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"2023042102571721900_ehac605-B12","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"2023042102571721900_ehac605-B13","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"2023042102571721900_ehac605-B14","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/jama.299.21.2524","article-title":"Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease","volume":"299","author":"Frikke-Schmidt","year":"2008","journal-title":"JAMA"},{"key":"2023042102571721900_ehac605-B15","doi-asserted-by":"crossref","first-page":"E500","DOI":"10.1210\/jc.2010-0450","article-title":"Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease","volume":"95","author":"Haase","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2023042102571721900_ehac605-B16","doi-asserted-by":"crossref","first-page":"E248","DOI":"10.1210\/jc.2011-1846","article-title":"LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals","volume":"97","author":"Haase","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2023042102571721900_ehac605-B17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.bbalip.2011.08.006","article-title":"Increased risk of coronary artery disease in caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT","volume":"1821","author":"Tietjen","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2023042102571721900_ehac605-B18","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1194\/jlr.M088203","article-title":"Genetic and secondary causes of severe HDL deficiency and cardiovascular disease","volume":"59","author":"Geller","year":"2018","journal-title":"J Lipid Res"},{"key":"2023042102571721900_ehac605-B19","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1210\/jc.2008-1342","article-title":"Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease","volume":"94","author":"Johannsen","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2023042102571721900_ehac605-B20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.atherosclerosis.2018.12.024","article-title":"LDL Triglycerides, hepatic lipase activity, and coronary artery disease: an epidemiologic and Mendelian randomization study","volume":"282","author":"Silbernagel","year":"2019","journal-title":"Atherosclerosis"},{"key":"2023042102571721900_ehac605-B21","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/eurheartj\/ehy169","article-title":"Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease","volume":"39","author":"Helgadottir","year":"2018","journal-title":"Eur Heart J"},{"key":"2023042102571721900_ehac605-B22","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.aad3517","article-title":"Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease","volume":"351","author":"Zanoni","year":"2016","journal-title":"Science"},{"key":"2023042102571721900_ehac605-B23","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"2023042102571721900_ehac605-B24","doi-asserted-by":"crossref","first-page":"100044","DOI":"10.1194\/jlr.P120001000","article-title":"Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study","volume":"62","author":"Thomas","year":"2021","journal-title":"J Lipid Res"},{"key":"2023042102571721900_ehac605-B25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/CIRCRESAHA.117.311145","article-title":"Protein-Truncating variants at the cholesteryl ester transfer protein gene and risk for coronary heart disease","volume":"121","author":"Nomura","year":"2017","journal-title":"Circ Res"},{"key":"2023042102571721900_ehac605-B26","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP iInhibitors and statins with lipoprotein levels and cardiovascular risk","volume":"318","author":"Ference","year":"2017","journal-title":"JAMA"},{"key":"2023042102571721900_ehac605-B27","doi-asserted-by":"crossref","first-page":"e1003062","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"key":"2023042102571721900_ehac605-B28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-3-319-09665-0_9","article-title":"Mouse models of disturbed HDL metabolism","volume":"224","author":"Hoekstra","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"2023042102571721900_ehac605-B29","doi-asserted-by":"crossref","first-page":"e000519","DOI":"10.1161\/JAHA.113.000519","article-title":"Coronary heart disease risks associated with high levels of HDL cholesterol","volume":"3","author":"Wilkins","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2023042102571721900_ehac605-B30","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","article-title":"Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies","volume":"38","author":"Madsen","year":"2017","journal-title":"Eur Heart J"},{"key":"2023042102571721900_ehac605-B31","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/eurheartj\/ehx665","article-title":"U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies","volume":"39","author":"Madsen","year":"2018","journal-title":"Eur Heart J"},{"key":"2023042102571721900_ehac605-B32","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/cvr\/cvab164","article-title":"Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies","volume":"118","author":"Kjeldsen","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2023042102571721900_ehac605-B33","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.2174\/0929867325666180530110543","article-title":"Biological consequences of dysfunctional HDL","volume":"26","author":"Pirillo","year":"2019","journal-title":"Curr Med Chem"},{"key":"2023042102571721900_ehac605-B34","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL Cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"2023042102571721900_ehac605-B35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","article-title":"Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study","volume":"3","author":"Saleheen","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023042102571721900_ehac605-B36","doi-asserted-by":"crossref","first-page":"e016507","DOI":"10.1161\/JAHA.119.016507","article-title":"Anti-Inflammatory HDL function, incident cardiovascular events, and mortality: a secondary analysis of the JUPITER randomized clinical trial","volume":"9","author":"Ajala","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2023042102571721900_ehac605-B37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/0003-4819-150-2-200901200-00006","article-title":"High-density lipoprotein particle size and concentration and coronary risk","volume":"150","author":"El Harchaoui","year":"2009","journal-title":"Ann Intern Med"},{"key":"2023042102571721900_ehac605-B38","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jacc.2012.03.060","article-title":"High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: mESA (multi-ethnic study of atherosclerosis)","volume":"60","author":"Mackey","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2023042102571721900_ehac605-B39","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/CIRCULATIONAHA.111.073684","article-title":"Lipids and lipoproteins and risk of different vascular events in the MRC\/BHF heart protection study","volume":"125","author":"Parish","year":"2012","journal-title":"Circulation"},{"key":"2023042102571721900_ehac605-B40","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.amjcard.2015.01.015","article-title":"Relation of black race between high density lipoprotein cholesterol content, high density lipoprotein particles and coronary events (from the Dallas heart study)","volume":"115","author":"Chandra","year":"2015","journal-title":"Am J Cardiol"},{"key":"2023042102571721900_ehac605-B41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2006.09.001","article-title":"Multiple risk factor intervention trial research G. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome","volume":"195","author":"Kuller","year":"2007","journal-title":"Atherosclerosis"},{"key":"2023042102571721900_ehac605-B42","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1161\/CIRCULATIONAHA.120.044221","article-title":"HDL In the 21st century: a multifunctional roadmap for future HDL research","volume":"143","author":"Rohatgi","year":"2021","journal-title":"Circulation"},{"key":"2023042102571721900_ehac605-B43","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nsmb.2028","article-title":"Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma","volume":"18","author":"Huang","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"2023042102571721900_ehac605-B44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.mol.0000169349.38321.ad","article-title":"Apolipoprotein structural organization in high density lipoproteins: belts, bundles, hinges and hairpins","volume":"16","author":"Davidson","year":"2005","journal-title":"Curr Opin Lipidol"},{"key":"2023042102571721900_ehac605-B45","doi-asserted-by":"crossref","first-page":"159072","DOI":"10.1016\/j.bbalip.2021.159072","article-title":"The HDL proteome watch: compilation of studies leads to new insights on HDL function","volume":"1867","author":"Davidson","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2023042102571721900_ehac605-B46","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1021\/acs.jproteome.1c00429","article-title":"Reproducible determination of high-density lipoprotein proteotypes","volume":"20","author":"Goetze","year":"2021","journal-title":"J Proteome Res"},{"key":"2023042102571721900_ehac605-B47","first-page":"511","article-title":"Genetic epidemiology and associated diseases of APOL1: a narrative review","volume":"38","author":"Coker","year":"2021","journal-title":"West Afr J Med"},{"key":"2023042102571721900_ehac605-B48","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.atherosclerosis.2016.11.015","article-title":"High density lipoproteins are modulators of protease activity: implications in inflammation, complement activation, and atherothrombosis","volume":"259","author":"Gordon","year":"2017","journal-title":"Atherosclerosis"},{"key":"2023042102571721900_ehac605-B49","doi-asserted-by":"crossref","first-page":"e0150083","DOI":"10.1371\/journal.pone.0150083","article-title":"Lipoprotein X causes renal disease in LCAT deficiency","volume":"11","author":"Ossoli","year":"2016","journal-title":"PLoS One"},{"key":"2023042102571721900_ehac605-B50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11883-022-00987-y","article-title":"A nutrigenetic update on CETP gene-diet interactions on lipid-related outcomes","volume":"24","author":"Wuni","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"2023042102571721900_ehac605-B51","doi-asserted-by":"crossref","first-page":"754490","DOI":"10.3389\/fmed.2021.754490","article-title":"The apoM\/S1P Complex-A mediator in kidney biology and disease?","volume":"8","author":"Bisgaard","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2023042102571721900_ehac605-B52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11883-021-00930-7","article-title":"HDL-small RNA export, transport, and functional delivery in atherosclerosis","volume":"23","author":"Vickers","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"2023042102571721900_ehac605-B53","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1373\/clinchem.2010.155333","article-title":"HDL Measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events","volume":"57","author":"Rosenson","year":"2011","journal-title":"Clin Chem"},{"key":"2023042102571721900_ehac605-B54","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1161\/ATVBAHA.120.314609","article-title":"Protein-Defined subspecies of HDLs (high-density lipoproteins) and differential risk of coronary heart disease in 4 prospective studies","volume":"40","author":"Sacks","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B55","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1373\/clinchem.2016.257725","article-title":"The changing face of HDL and the best way to measure it","volume":"63","author":"Karathanasis","year":"2017","journal-title":"Clin Chem"},{"key":"2023042102571721900_ehac605-B56","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1161\/ATVBAHA.118.311607","article-title":"Distinct proteomic signatures in 16 HDL (high-density lipoprotein) subspecies","volume":"38","author":"Furtado","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B57","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/ATVBAHA.115.306138","article-title":"Novel pathways of apolipoprotein A-I metabolism in high-density lipoprotein of different sizes in humans","volume":"36","author":"Mendivil","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B58","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.pt.2010.05.005","article-title":"The trypanolytic factor-mechanism, impacts and applications","volume":"26","author":"Wheeler","year":"2010","journal-title":"Trends Parasitol"},{"key":"2023042102571721900_ehac605-B59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-319-09665-0_2","article-title":"HDL Biogenesis, remodeling, and catabolism","volume":"224","author":"Zannis","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"2023042102571721900_ehac605-B60","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/CIRCRESAHA.119.316424","article-title":"LDL Receptor regulates the reverse transport of macrophage-derived unesterified cholesterol via concerted action of the HDL-LDL axis: insight from mouse models","volume":"127","author":"Cedo","year":"2020","journal-title":"Circ Res"},{"key":"2023042102571721900_ehac605-B61","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41569-021-00538-z","article-title":"High-density lipoproteins, reverse cholesterol transport and atherogenesis","volume":"18","author":"Pownall","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2023042102571721900_ehac605-B62","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1194\/jlr.M050021","article-title":"Apolipoprotein M modulates erythrocyte efflux and tubular reabsorption of sphingosine-1-phosphate","volume":"55","author":"Sutter","year":"2014","journal-title":"J Lipid Res"},{"key":"2023042102571721900_ehac605-B63","doi-asserted-by":"crossref","first-page":"14983","DOI":"10.1038\/s41598-017-15043-y","article-title":"Apolipoprotein M mediates sphingosine-1-phosphate efflux from erythrocytes","volume":"7","author":"Christensen","year":"2017","journal-title":"Sci Rep"},{"key":"2023042102571721900_ehac605-B64","doi-asserted-by":"crossref","first-page":"24020","DOI":"10.1074\/jbc.R114.583658","article-title":"Molecular mechanisms of cellular cholesterol efflux","volume":"289","author":"Phillips","year":"2014","journal-title":"J Biol Chem"},{"key":"2023042102571721900_ehac605-B65","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCRESAHA.119.312617","article-title":"HDL And reverse cholesterol transport","volume":"124","author":"Ouimet","year":"2019","journal-title":"Circ Res"},{"key":"2023042102571721900_ehac605-B66","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.atherosclerosis.2018.06.881","article-title":"Endocytosis of lipoproteins","volume":"275","author":"Zanoni","year":"2018","journal-title":"Atherosclerosis"},{"key":"2023042102571721900_ehac605-B67","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1161\/ATVBAHA.119.312382","article-title":"Targeted deletion of hepatocyte Abca1 increases plasma HDL (high-density lipoprotein) reverse cholesterol transport via the LDL (low-density lipoprotein) receptor","volume":"39","author":"Bashore","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B68","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1161\/01.ATV.0000161928.16334.dd","article-title":"Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion","volume":"25","author":"Brousseau","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B69","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3390\/cells10051061","article-title":"HDL In immune-inflammatory responses: implications beyond cardiovascular diseases","volume":"10","author":"Bonacina","year":"2021","journal-title":"Cells"},{"key":"2023042102571721900_ehac605-B70","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/ncomms15010","article-title":"Thermogenic adipocytes promote HDL turnover and reverse cholesterol transport","volume":"8","author":"Bartelt","year":"2017","journal-title":"Nat Commun"},{"key":"2023042102571721900_ehac605-B71","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/ATVBAHA.117.309880","article-title":"Targeted deletion of adipocyte Abca1 (ATP-binding cassette transporter A1) impairs diet-induced obesity","volume":"38","author":"Cuffe","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B72","doi-asserted-by":"crossref","first-page":"159058","DOI":"10.1016\/j.bbalip.2021.159058","article-title":"High-density lipoproteins (HDL): novel function and therapeutic applications","volume":"1867","author":"Darabi","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2023042102571721900_ehac605-B73","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3390\/cells10051041","article-title":"The endothelium is both a target and a barrier of HDL\u2019s protective functions","volume":"10","author":"Robert","year":"2021","journal-title":"Cells"},{"key":"2023042102571721900_ehac605-B74","doi-asserted-by":"crossref","first-page":"e013531","DOI":"10.1161\/JAHA.119.013531","article-title":"Role of high-density lipoproteins in cholesterol homeostasis and glycemic control","volume":"9","author":"Manandhar","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2023042102571721900_ehac605-B75","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/89986","article-title":"High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase","volume":"7","author":"Yuhanna","year":"2001","journal-title":"Nat Med"},{"key":"2023042102571721900_ehac605-B76","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.2784","article-title":"High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3","volume":"15","author":"De Nardo","year":"2014","journal-title":"Nat Immunol"},{"key":"2023042102571721900_ehac605-B77","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.immuni.2016.11.008","article-title":"Cholesterol accumulation in CD11c(+) immune cells is a causal and targetable factor in autoimmune disease","volume":"45","author":"Ito","year":"2016","journal-title":"Immunity"},{"key":"2023042102571721900_ehac605-B78","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2006478118","article-title":"Loss of hepatic miR-33 improves metabolic homeostasis and liver function without altering body weight or atherosclerosis","volume":"118","author":"Price","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023042102571721900_ehac605-B79","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.tem.2017.02.001","article-title":"SR-BI: a multifunctional receptor in cholesterol homeostasis and atherosclerosis","volume":"28","author":"Linton","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"2023042102571721900_ehac605-B80","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/s41598-018-38014-3","article-title":"Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle","volume":"9","author":"Tang","year":"2019","journal-title":"Sci Rep"},{"key":"2023042102571721900_ehac605-B81","doi-asserted-by":"crossref","first-page":"eaar5551","DOI":"10.1126\/science.aar5551","article-title":"Sphingosine 1-phosphate: lipid signaling in pathology and therapy","volume":"366","author":"Cartier","year":"2019","journal-title":"Science"},{"key":"2023042102571721900_ehac605-B82","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/ATVBAHA.121.316725","article-title":"Apolipoprotein M and sphingosine-1-phosphate receptor 1 promote the transendothelial transport of high-density lipoprotein","volume":"41","author":"Velagapudi","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B83","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2019.04.227","article-title":"High-density lipoproteins induce miR-223-3p biogenesis and export from myeloid cells: role of scavenger receptor BI-mediated lipid transfer","volume":"286","author":"Cuesta Torres","year":"2019","journal-title":"Atherosclerosis"},{"key":"2023042102571721900_ehac605-B84","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.atherosclerosis.2014.11.017","article-title":"Ecto-F1-ATPase\/P2Y pathways in metabolic and vascular functions of high density lipoproteins","volume":"238","author":"Martinez","year":"2015","journal-title":"Atherosclerosis"},{"key":"2023042102571721900_ehac605-B85","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jcmgh.2014.12.006","article-title":"Anti-inflammatory function of high-density lipoproteins via autophagy of IkappaB kinase","volume":"1","author":"Gerster","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2023042102571721900_ehac605-B86","doi-asserted-by":"crossref","first-page":"158537","DOI":"10.1016\/j.bbalip.2019.158537","article-title":"Interleukin 10 promotes macrophage uptake of HDL and LDL by stimulating fluid-phase endocytosis","volume":"1865","author":"Lucero","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2023042102571721900_ehac605-B87","doi-asserted-by":"crossref","first-page":"jcs258644","DOI":"10.1242\/jcs.258644","article-title":"HDLs extract lipophilic drugs from cells","volume":"135","author":"Zheng","year":"2022","journal-title":"J Cell Sci"},{"key":"2023042102571721900_ehac605-B88","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3390\/biom10040598","article-title":"High-Density lipoproteins are bug scavengers","volume":"10","author":"Meilhac","year":"2020","journal-title":"Biomolecules"},{"key":"2023042102571721900_ehac605-B89","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.gene.2015.04.088","article-title":"Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles","volume":"567","author":"Mackness","year":"2015","journal-title":"Gene"},{"key":"2023042102571721900_ehac605-B90","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.jacc.2012.06.057","article-title":"Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up","volume":"60","author":"Rallidis","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2023042102571721900_ehac605-B91","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1161\/ATVBAHA.118.311987","article-title":"Recombinant LCAT (lecithin:cholesterol acyltransferase) rescues defective HDL (high-density lipoprotein)-mediated endothelial protection in acute coronary syndrome","volume":"39","author":"Ossoli","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B92","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/978-3-319-09665-0_15","article-title":"HDL In infectious diseases and sepsis","volume":"224","author":"Pirillo","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"2023042102571721900_ehac605-B93","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s42255-020-00324-0","article-title":"HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry","volume":"2","author":"Wei","year":"2020","journal-title":"Nat Metab"},{"key":"2023042102571721900_ehac605-B94","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3390\/antiox10020209","article-title":"Native high-density lipoproteins (HDL) with higher paraoxonase exerts a potent antiviral effect against SARS-CoV-2 (COVID-19), while glycated HDL lost the antiviral activity","volume":"10","author":"Cho","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"2023042102571721900_ehac605-B95","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.trsl.2016.02.008","article-title":"Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy","volume":"173","author":"Annema","year":"2016","journal-title":"Transl Res"},{"key":"2023042102571721900_ehac605-B96","doi-asserted-by":"crossref","first-page":"e131491","DOI":"10.1172\/jci.insight.131491","article-title":"Structure-function relationships of HDL in diabetes and coronary heart disease","volume":"5","author":"Cardner","year":"2020","journal-title":"JCI Insight"},{"key":"2023042102571721900_ehac605-B97","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2013.02.009","article-title":"Abnormal high-density lipoprotein induces endothelial dysfunction via activation of toll-like receptor-2","volume":"38","author":"Speer","year":"2013","journal-title":"Immunity"},{"key":"2023042102571721900_ehac605-B98","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1172\/JCI42946","article-title":"Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease","volume":"121","author":"Besler","year":"2011","journal-title":"J Clin Invest"},{"key":"2023042102571721900_ehac605-B99","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"2023042102571721900_ehac605-B100","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1177\/2047487319894114","article-title":"Free cholesterol transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis underlies the U-shape relationship between HDL-cholesterol and cardiovascular disease","volume":"27","author":"Feng","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2023042102571721900_ehac605-B101","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz265","article-title":"Low high-density lipoprotein cholesterol to monitor long-term average increased triglycerides","author":"Langsted","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2023042102571721900_ehac605-B102","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12944-018-0732-6","article-title":"Relation between high density lipoprotein particles concentration and cardiovascular events: a meta-analysis","volume":"17","author":"Wu","year":"2018","journal-title":"Lipids Health Dis"},{"key":"2023042102571721900_ehac605-B103","doi-asserted-by":"crossref","first-page":"e58361","DOI":"10.7554\/eLife.58361","article-title":"A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease","volume":"10","author":"Zhao","year":"2021","journal-title":"Elife"},{"key":"2023042102571721900_ehac605-B104","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.atherosclerosis.2014.12.006","article-title":"Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients","volume":"238","author":"Masana","year":"2015","journal-title":"Atherosclerosis"},{"key":"2023042102571721900_ehac605-B105","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1161\/CIRCULATIONAHA.113.002670","article-title":"Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis","volume":"128","author":"Boekholdt","year":"2013","journal-title":"Circulation"},{"key":"2023042102571721900_ehac605-B106","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.atherosclerosis.2020.02.002","article-title":"Apolipoprotein A-I concentrations and risk of coronary artery disease: a Mendelian randomization study","volume":"299","author":"Karjalainen","year":"2020","journal-title":"Atherosclerosis"},{"key":"2023042102571721900_ehac605-B107","first-page":"3007","article-title":"Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk","volume":"36","author":"Zewinger","year":"2015","journal-title":"Eur Heart J"},{"key":"2023042102571721900_ehac605-B108","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2215\/CJN.06560714","article-title":"Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis","volume":"10","author":"Kopecky","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023042102571721900_ehac605-B109","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCULATIONAHA.112.108753","article-title":"Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling","volume":"127","author":"Riwanto","year":"2013","journal-title":"Circulation"},{"key":"2023042102571721900_ehac605-B110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2020.04.015","article-title":"High density lipoprotein functionality and cardiovascular events and mortality: a systematic review and meta-analysis","volume":"302","author":"Soria-Florido","year":"2020","journal-title":"Atherosclerosis"},{"key":"2023042102571721900_ehac605-B111","doi-asserted-by":"crossref","first-page":"100125","DOI":"10.1016\/j.jlr.2021.100125","article-title":"Lysis reagents, cell numbers, and calculation method influence high-throughput measurement of HDL-mediated cholesterol efflux capacity","volume":"62","author":"Schachtl-Riess","year":"2021","journal-title":"J Lipid Res"},{"key":"2023042102571721900_ehac605-B112","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jacc.2015.09.013","article-title":"Cholesterol efflux capacity and Pre-Beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib","volume":"66","author":"Nicholls","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023042102571721900_ehac605-B113","doi-asserted-by":"crossref","DOI":"10.1111\/joim.13479","article-title":"Genetic and observational evidence: no independent role for cholesterol efflux over static high-density lipoprotein concentration measures in coronary heart disease risk assessment","author":"Kuusisto","year":"2022","journal-title":"J Intern Med"},{"key":"2023042102571721900_ehac605-B114","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2019.01.073","article-title":"Association of an HDL apolipoproteomic score with coronary atherosclerosis and cardiovascular death","volume":"73","author":"Natarajan","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023042102571721900_ehac605-B115","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/ATVBAHA.120.314050","article-title":"Novel insights from human studies on the role of high-density lipoprotein in mortality and noncardiovascular disease","volume":"41","author":"Madsen","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B116","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.jacc.2016.08.038","article-title":"High-Density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART study","volume":"68","author":"Ko","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2023042102571721900_ehac605-B117","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.2215\/CJN.00730116","article-title":"High density lipoprotein cholesterol and the risk of all-cause mortality among U","volume":"11","author":"Bowe","year":"2016","journal-title":"S. Veterans. Clin J Am Soc Nephrol"},{"key":"2023042102571721900_ehac605-B118","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1194\/jlr.M079822","article-title":"Polygenic determinants in extremes of high-density lipoprotein cholesterol","volume":"58","author":"Dron","year":"2017","journal-title":"J Lipid Res"},{"key":"2023042102571721900_ehac605-B119","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1161\/ATVBAHA.119.313381","article-title":"Causal inference for genetically determined levels of high-density lipoprotein cholesterol and risk of infectious disease","volume":"40","author":"Trinder","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-020-00963-6","article-title":"Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals","volume":"13","author":"Pedersen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2023042102571721900_ehac605-B121","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MOL.0000000000000577","article-title":"Molecular regulation of plasma lipid levels during systemic inflammation and sepsis","volume":"30","author":"Trinder","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"2023042102571721900_ehac605-B122","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jcrc.2016.11.041","article-title":"Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis","volume":"38","author":"Cirstea","year":"2017","journal-title":"J Crit Care"},{"key":"2023042102571721900_ehac605-B123","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/CIRCULATIONAHA.120.048568","article-title":"Inhibition of cholesteryl ester transfer protein preserves high-density lipoprotein cholesterol and improves survival in sepsis","volume":"143","author":"Trinder","year":"2021","journal-title":"Circulation"},{"key":"2023042102571721900_ehac605-B124","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1373\/clinchem.2018.299636","article-title":"Low HDL cholesterol and high risk of autoimmune disease: two population-based cohort studies including 117341 individuals","volume":"65","author":"Madsen","year":"2019","journal-title":"Clin Chem"},{"key":"2023042102571721900_ehac605-B125","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.plipres.2018.06.001","article-title":"High density lipoprotein cholesterol and cancer: marker or causative?","volume":"71","author":"Pirro","year":"2018","journal-title":"Prog Lipid Res"},{"key":"2023042102571721900_ehac605-B126","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3945\/ajcn.115.124321","article-title":"Lipid biomarkers and long-term risk of cancer in the women\u2019s health study","volume":"103","author":"Chandler","year":"2016","journal-title":"Am J Clin Nutr"},{"key":"2023042102571721900_ehac605-B127","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamacardio.2016.1884","article-title":"Association of lipid fractions with risks for coronary artery disease and diabetes","volume":"1","author":"White","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2023042102571721900_ehac605-B128","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.2337\/db14-1710","article-title":"Using genetic variants to assess the relationship between circulating lipids and type 2 diabetes","volume":"64","author":"Fall","year":"2015","journal-title":"Diabetes"},{"key":"2023042102571721900_ehac605-B129","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.2337\/db14-1603","article-title":"HDL Cholesterol and risk of type 2 diabetes: a Mendelian randomization study","volume":"64","author":"Haase","year":"2015","journal-title":"Diabetes"},{"key":"2023042102571721900_ehac605-B130","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvac025","article-title":"The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis","author":"Dangas","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023042102571721900_ehac605-B131","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.diabet.2018.02.005","article-title":"Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk","volume":"44","author":"Masson","year":"2018","journal-title":"Diabetes Metab"},{"key":"2023042102571721900_ehac605-B132","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1161\/CIRCULATIONAHA.108.843219","article-title":"High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus","volume":"119","author":"Drew","year":"2009","journal-title":"Circulation"},{"key":"2023042102571721900_ehac605-B133","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.kint.2015.12.034","article-title":"Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression","volume":"89","author":"Bowe","year":"2016","journal-title":"Kidney Int"},{"key":"2023042102571721900_ehac605-B134","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.291.7.844","article-title":"Predictors of new-onset kidney disease in a community-based population","volume":"291","author":"Fox","year":"2004","journal-title":"Jama"},{"key":"2023042102571721900_ehac605-B135","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1523-1755.2000.00165.x","article-title":"Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study","volume":"58","author":"Muntner","year":"2000","journal-title":"Kidney Int"},{"key":"2023042102571721900_ehac605-B136","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/ATVBAHA.116.308393","article-title":"Is high-density lipoprotein cholesterol causally related to kidney function? Evidence from genetic epidemiological studies","volume":"36","author":"Coassin","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B137","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.ajkd.2017.06.011","article-title":"HDL Cholesterol, LDL cholesterol, and triglycerides as risk factors for CKD: a Mendelian randomization study","volume":"71","author":"Lanktree","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2023042102571721900_ehac605-B138","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3389\/fgene.2019.00415","article-title":"Causal effects of genetically predicted cardiovascular risk factors on chronic kidney disease: a two-sample Mendelian randomization study","volume":"10","author":"Liu","year":"2019","journal-title":"Front Genet"},{"key":"2023042102571721900_ehac605-B139","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fphar.2016.00323","article-title":"High-density lipoproteins and apolipoprotein A-I: potential new players in the prevention and treatment of lung disease","volume":"7","author":"Gordon","year":"2016","journal-title":"Front Pharmacol"},{"key":"2023042102571721900_ehac605-B140","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ophtha.2017.03.042","article-title":"Mendelian Randomization implicates high-density lipoprotein cholesterol-associated mechanisms in etiology of age-related macular degeneration","volume":"124","author":"Burgess","year":"2017","journal-title":"Ophthalmology"},{"key":"2023042102571721900_ehac605-B141","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ophtha.2018.09.045","article-title":"Increased high-density lipoprotein levels associated with age-related macular degeneration: evidence from the EYE-RISK and European eye epidemiology consortia","volume":"126","author":"Colijn","year":"2019","journal-title":"Ophthalmology"},{"key":"2023042102571721900_ehac605-B142","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ije\/dyaa178","article-title":"The effects of eight serum lipid biomarkers on age-related macular degeneration risk: a Mendelian randomization study","volume":"50","author":"Han","year":"2021","journal-title":"Int J Epidemiol"},{"key":"2023042102571721900_ehac605-B143","doi-asserted-by":"crossref","first-page":"e2749","DOI":"10.1210\/clinem\/dgab095","article-title":"Elevated apolipoprotein A1 and HDL cholesterol associated with age-related macular degeneration: 2 population cohorts","volume":"106","author":"Nordestgaard","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2023042102571721900_ehac605-B144","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamacardio.2021.3728","article-title":"Long-term benefits and Harms associated with genetic cholesteryl ester transfer protein deficiency in the general population","volume":"7","author":"Nordestgaard","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2023042102571721900_ehac605-B145","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0022-2275(20)34780-5","article-title":"Animal lipoproteins: chemistry, structure, and comparative aspects","volume":"21","author":"Chapman","year":"1980","journal-title":"J Lipid Res"},{"key":"2023042102571721900_ehac605-B146","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-3-030-41769-7_2","article-title":"Crustacean hemolymph lipoproteins","volume":"94","author":"Hoeger","year":"2020","journal-title":"Subcell Biochem"},{"key":"2023042102571721900_ehac605-B147","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1515\/bmc.2010.012","article-title":"Lipoprotein assembly and function in an evolutionary perspective","volume":"1","author":"Van der Horst","year":"2010","journal-title":"Biomol Concepts"},{"key":"2023042102571721900_ehac605-B148","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1161\/CIRCRESAHA.120.317721","article-title":"LDL Contributes to reverse cholesterol transport","volume":"127","author":"von Eckardstein","year":"2020","journal-title":"Circ Res"},{"key":"2023042102571721900_ehac605-B149","doi-asserted-by":"crossref","first-page":"E102","DOI":"10.1152\/ajpendo.00069.2020","article-title":"Identification of scavenger receptor BI as a potential screening candidate for congenital primary adrenal insufficiency in humans","volume":"319","author":"Hoekstra","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2023042102571721900_ehac605-B150","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med"},{"key":"2023042102571721900_ehac605-B151","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","article-title":"Trials and tribulations of CETP inhibitors","volume":"122","author":"Tall","year":"2018","journal-title":"Circ Res"},{"key":"2023042102571721900_ehac605-B152","doi-asserted-by":"crossref","first-page":"e018136","DOI":"10.1161\/JAHA.120.018136","article-title":"Effect of anacetrapib on cholesterol efflux capacity: a substudy of the DEFINE trial","volume":"9","author":"Metzinger","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2023042102571721900_ehac605-B153","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.atherosclerosis.2019.04.211","article-title":"Evacetrapib reduces prebeta-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes","volume":"285","author":"Chen","year":"2019","journal-title":"Atherosclerosis"},{"key":"2023042102571721900_ehac605-B154","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jacl.2016.06.006","article-title":"Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses","volume":"10","author":"van Capelleveen","year":"2016","journal-title":"J Clin Lipidol"},{"key":"2023042102571721900_ehac605-B155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/ATVBAHA.121.317181","article-title":"Pharmacological inhibition of CETP (cholesteryl ester transfer protein) increases HDL (high-density lipoprotein) that contains ApoC3 and other HDL subspecies associated with higher risk of coronary heart disease","volume":"42","author":"Furtado","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B156","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1172\/JCI114558","article-title":"Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit","volume":"85","author":"Badimon","year":"1990","journal-title":"J Clin Invest"},{"key":"2023042102571721900_ehac605-B157","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1073\/pnas.91.20.9607","article-title":"Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse","volume":"91","author":"Plump","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023042102571721900_ehac605-B158","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/353265a0","article-title":"Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI","volume":"353","author":"Rubin","year":"1991","journal-title":"Nature"},{"key":"2023042102571721900_ehac605-B159","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1161\/01.CIR.103.15.1949","article-title":"Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the limone sul garda study","volume":"103","author":"Sirtori","year":"2001","journal-title":"Circulation"},{"key":"2023042102571721900_ehac605-B160","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0021-9150(85)90063-2","article-title":"Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns","volume":"58","author":"Franceschini","year":"1985","journal-title":"Atherosclerosis"},{"key":"2023042102571721900_ehac605-B161","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1161\/01.ATV.19.5.1257","article-title":"Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice","volume":"19","author":"Franceschini","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B162","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"Jama"},{"key":"2023042102571721900_ehac605-B163","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jamacardio.2018.2112","article-title":"Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I Milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT trial: a randomized clinical trial","volume":"3","author":"Nicholls","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2023042102571721900_ehac605-B164","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cca.2017.12.031","article-title":"HDL Acceptor capacities for cholesterol efflux from macrophages and lipid transfer are both acutely reduced after myocardial infarction","volume":"478","author":"Soares","year":"2018","journal-title":"Clin Chim Acta"},{"key":"2023042102571721900_ehac605-B165","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"Jama"},{"key":"2023042102571721900_ehac605-B166","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jcph.194","article-title":"A multiple ascending dose study of CSL112, an infused formulation of ApoA-I","volume":"54","author":"Easton","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2023042102571721900_ehac605-B167","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/ATVBAHA.113.301981","article-title":"Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux","volume":"33","author":"Diditchenko","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102571721900_ehac605-B168","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1161\/CIRCULATIONAHA.116.025687","article-title":"Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (ApoA-I event reducing in ischemic syndromes I)","volume":"134","author":"Michael Gibson","year":"2016","journal-title":"Circulation"},{"key":"2023042102571721900_ehac605-B169","doi-asserted-by":"crossref","first-page":"e002171","DOI":"10.1161\/JAHA.115.002171","article-title":"Infusion of reconstituted high-density lipoprotein, CSL112, in patients with atherosclerosis: safety and pharmacokinetic results from a phase 2a randomized clinical trial","volume":"4","author":"Tricoci","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2023042102571721900_ehac605-B170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ahj.2020.10.052","article-title":"Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction","volume":"231","author":"Gibson","year":"2021","journal-title":"Am Heart J"},{"key":"2023042102571721900_ehac605-B171","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2013.10.018","article-title":"CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice","volume":"232","author":"Tardy","year":"2014","journal-title":"Atherosclerosis"},{"key":"2023042102571721900_ehac605-B172","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","article-title":"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial","volume":"35","author":"Tardif","year":"2014","journal-title":"Eur Heart J"},{"key":"2023042102571721900_ehac605-B173","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/joim.13404","article-title":"The HDL mimetic CER-001 remodels plasma lipoproteins and reduces kidney lipid deposits in inherited lecithin:cholesterol acyltransferase deficiency","volume":"291","author":"Pavanello","year":"2022","journal-title":"J Intern Med"},{"key":"2023042102571721900_ehac605-B174","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.7326\/L20-1300","article-title":"Administration of the high-density lipoprotein mimetic CER-001 for inherited lecithin-cholesterol acyltransferase deficiency","volume":"174","author":"Faguer","year":"2021","journal-title":"Ann Intern Med"},{"key":"2023042102571721900_ehac605-B175","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3390\/biomedicines10040754","article-title":"First recombinant high-density lipoprotein particles administration in a severe ICU COVID-19 patient, a multi-omics exploratory investigation","volume":"10","author":"Tanaka","year":"2022","journal-title":"Biomedicines"},{"key":"2023042102571721900_ehac605-B176","doi-asserted-by":"crossref","first-page":"e014572","DOI":"10.1161\/JAHA.119.014572","article-title":"MEDI6012: recombinant human lecithin cholesterol acyltransferase, high-density lipoprotein, and low-density lipoprotein receptor-mediated reverse cholesterol transport","volume":"10","author":"George","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/16\/1394\/50050647\/ehac605.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/16\/1394\/50050647\/ehac605.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T11:42:11Z","timestamp":1728128531000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/16\/1394\/6807326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":176,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,11,7]]},"published-print":{"date-parts":[[2023,4,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac605","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,21]]},"published":{"date-parts":[[2022,11,7]]}}}